SRT-100

2020年12月美国Sensus Healthcare正式授权Ekpac Healthcare(香港维昌医疗)为SRT-100中国大陆及香港地区的独家代理

  1. 行业

SRT-100浅层放射设备国内独家代理维昌集团



       维昌洋行(中国)有限公司日前宣布已与美国Sensus Healthcare,Inc签订新的独家代理协议,在中国大陆和香港市场独家代理销售Sensus SRT-100系统。这也意味着维昌集团成为srt100浅层放射治疗设备中国国内独家代理经销商。根据双方约定,本独家代理协议已经2021年1月1日起生效。srt100浅层放射治疗设备目前在中国的公立和私立医院以及私人诊所装机约40台。Sensus期待维昌集团成为srt100浅层放射治疗设备中国国内独家代理经销商后能更好的服务各级医疗机构,提高SRT-100浅层放射治疗设备在国内的临床应用和普及。

  SRT-100系统使用了Sensus特有的低能量X射线技术,即浅层放射疗法(SRT)。Ekpac Healthcare Technologies的总经理Julie Xue在评论该合作协议时说:“我们很高兴Sensus Healthcare选择Ekpac Healthcare作为为srt100浅层放射治疗设备独家代理商,并期待携手合作,共同开拓SRT-100系统在中国的市场。维昌洋行在中国已有100多年的历史,多年来成功将海外先进技术和设备结合国际融资引入中国。SRT-100浅层放射治疗设备在疤痕疙瘩和非黑色素瘤皮肤癌治疗方面具有独特的特性和优势,我们有信心取得成就,并将为中国的患者和社会带来福音。”

  “我们很高兴维昌集团能成为srt100浅层放射治疗设备中国国内的独家代理经销商SRT-100浅层放射治疗设备具有独特的技术优势,早在2013年美国FDA就对SRT-100出具证书,确认srt100浅层放射治疗设备在疤痕治疗方面具有绝对疗效,中国拥有世界20%以上人口,在这个市场上我们看到了未来几年乃至更长时间内的重大机遇。中国CFDA分别于2014年和2017年就批准了SRT-100用于治疗非黑色素瘤皮肤癌和瘢痕疙瘩”。Benson Sun评论:“我们相信,维昌集团成为srt100浅层放射治疗设备国内独家代理经销商后,凭借其在中国的大型医疗设备市场丰富的运营经验和分销网络,他们能更好的服务各级医疗机构,推广SRT-100浅层放射治疗系统,为需要帮助的患者提供无创、高效和改变生活的解决方案。”

关于维昌
  

      维昌美迪医疗技术(北京)有限公司隶属于维昌洋行(中国)有限公司。维昌洋行成立于1910年,深耕中国市场100多年,是在国际上享有盛誉的百年企业。从80年代开始,随着改革开放的大潮,维昌美迪医疗技术(北京)有限公司开始负责集团外国政府贷款医疗行业的业务,30多年来通过与国内各级医疗器械公司和医疗机构合作,共成功完成150多家国内医院的项目,无论从数量还是执行质量,均在业界遥遥领先。

  大约30年前,维昌集团开始专注于发展其医疗板块业务,目前已为中国17个省份的150多家医院提供服务。集团优势在于利用全球的先进技术和产品来满足中国的需求,同时利用其全球资源为客户提供国际融资。在项目的执行过程中,维昌美迪医疗技术(北京)有限公司积累了丰富的项目经验,与国外银行、国内政府部门、全球主流供应商、国内医院客户建立了良好的合作关系,也成了很多国外企业、产品进入中国的桥梁。目前,维昌美迪医疗技术(北京)有限公司涵盖维昌美迪医疗技术(北京)有限公司、维昌康健医疗器械(上海)有限公司、EKPAC Healthcare Limited及海外公司等多家独立法人机构,业务范围遍及欧美、日韩、东南亚、中国大陆和台湾等地,业务领域也由单纯的政府贷款发展到产品代理、出口信贷等业务多元化发展,业务领域涵盖核医学、内分泌、护理、检验、康复、放射、放疗、神外等等。

联系维昌

  中国大陆地区SRT-100浅层放射治疗设备考察引进及技术支持,请致电维昌美迪医疗技术(北京)有限公司。
  销售代表张经理,电话:13911567019


 



附:Sensus Healthcare,Inc官网原文:

Agreement is for the treatment of non-melanoma skin cancer and keloids, covers China and Hong Kong and is effective January 1, 2021

BOCA RATON, Fla. (December 15, 2020) – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that it has entered into a new exclusive distribution agreement with Ekpac Healthcare Ltd. to market Sensus SRT-100™ systems in China and Hong Kong. This agreement is effective as of January 1, 2021. Sensus currently has 40 units installed throughout China in public and private hospitals as well as private clinics. It expects this relationship to accelerate SRT-100 unit population in the region.
SRT-100 systems utilize Sensus’ proprietary low-energy x-ray technology known as superficial radiation therapy (SRT). China, which has more than 20% of the world’s population, approved the SRT-100 for the treatment of non-melanoma skin cancer and the prevention of scars following keloidectomy in 2014 and 2017, respectively. Sensus recently renewed its focus on international sales, including Asia, with the appointment of Benson Suen as Vice President International Sales July 2020.
Commenting on the agreement, Julie Xue, General Manager of Ekpac Healthcare Technologies, said, “We are delighted Sensus Healthcare has selected Ekpac Healthcare as its exclusive distributor, and look forward to working hand-in-hand to sell SRT-100 systems. Ekpac has more than 100 years of history in China, and is regarded as one of the most successful enterprises to bring advanced technology and devices – along with favorable financing – into China from overseas. SRT-100 systems have numerous compelling features and benefits. With the joint efforts of our two companies, we are confident tremendous success will be achieved and significant benefits will be delivered to patients across China.”
“We are excited to have Ekpac Healthcare as our partner in China, a market where we see significant opportunity over the next few years and beyond,” said Mr. Suen. “We believe that with Ekpac’s experience and their network for medical device distribution across China, they will be successful in selling SRT-100 machines to private clinics and public hospitals. In China and around the world, our systems offer non-invasive, highly efficacious and life-changing solutions to patients who are in need.”
About EKPAC Group
Ekpac Healthcare is part of EKPAC Group, which was founded in Sweden more than 110 years ago to import Swedish brands into China. Approximately 30 years ago Ekpac Healthcare began to focus on developing its healthcare business, and now supplies more than 150 hospitals in 17 provinces in China. Its strength is to bridge the latest needs in China with appropriate global advanced technologies, while leveraging its global network to provide clients with third-party financing for those technologies.

SRT的优势

除了消除手术后感染和复发的风险外,SRT-100还为患者和医生提供安全有效的治疗选择等多种优势,包括:

  1. 超过95%以上的临床治愈率
  2. 无麻醉,切口,出血,缝合或疼痛
  3. 正常生活不受限制
  4. 不会形成明显的疤痕恢复更好
  5. 一次到位无需术后重建手术
SRT总代理:维昌美迪(北京)有限公司
设备销售电话:13911567019